| High-income North America |
| Prevalence |
258 142 (225 327–295 461) |
478 573 (426 090–537 100) |
526 205 (471 867–585 743) |
733 490 (664 602–818 883) |
2 017 260 (1 870 427–2 183 386) |
| Cases per 100 000 |
1502 (1311–1719) |
2129 (1895–2389) |
2236 (2005–2489) |
3113 (2821–3475) |
2216 (2054–2398) |
| YLD |
12 408 (8680–17 110) |
22 325 (15 402–30 559) |
26 443 (18 237–36 819) |
30 600 (21 450–41 400) |
93 525 (65 864–126 933) |
| Rate per 100 000 |
72 (50–100) |
99 (69–136) |
112 (77–156) |
130 (91–176) |
103 (72–139) |
| Western Europe |
| Prevalence |
226 464 (198 409–259 596) |
454 724 (401 634–515 000) |
510 865 (453 338–573 776) |
854951 (768 534–958 165) |
2 064471 (1 900 504–2 243 406) |
| Cases per 100 000 |
1275 (1 1 17–1462) |
1933 (1708–2190) |
2198 (1951–2469) |
3646 (3277–4086) |
2237 (2059–2431) |
| YLD |
9166 (6304–12 735) |
16 542 (1 1 121–23 162) |
18 457 (12 695–25 847) |
24027 (16478–34 327) |
69 441 (48 083–96 832) |
| Rate per 100 000 |
52 (35–72) |
70 (47–98) |
79 (55–111) |
102 (70–146) |
75 (52–105) |
| Central Europe, Eastern Europe, and Central Asia |
| Prevalence |
446 534 (393 229–505 136) |
867 575 (761 631–978 052) |
853 600 (759 658–961 526) |
1 156 592 (1 039 959–1 289 852) |
3 355 115 (3 098 21 1–3 626 580) |
| Cases per 100 000 |
1969 (1734–2227) |
3155 (2769–3556) |
3545 (3155–3993) |
5066 (4555–5649) |
3276 (3025–3541) |
| YLD |
19 754 (13 847–27 355) |
34 888 (23 943–48 270) |
34 657 (23 805–47 919) |
38 964 (27 198–53 796) |
130 484 (91 327–179 383) |
| Rate per 100 000 |
87 (61–121) |
127 (87–176) |
144 (99–199) |
171 (119–236) |
127 (89–175) |
| Latin America and the Caribbean |
| Prevalence |
843 578 (744 767–954 872) |
1 640 439 (1 443 332–1 839 080) |
1 853 695 (1 648 833–2 080 510) |
2 670 666 (2 406 587–2 973 854) |
7 076 049 (6 546 644–7 652 670) |
| Cases per 100 000 |
2074 (1831–2348) |
3317 (2919–3719) |
3762 (3347–4223) |
5347 (4818–5954) |
3546 (3280–3835) |
| YLD |
36 917 (25 862–51 437) |
64 279 (43 830–88 858) |
72 599 (50 013–101 588) |
87 004 (60 705–120 938) |
265 671 (184402–365 704) |
| Rate per 100 000 |
91 (64–126) |
130 (89–180) |
147 (102–206) |
174 (122–242) |
133 (92–183) |
| Southeast Asia, East Asia, and Oceania |
| Prevalence |
2 937 855 (2 637 971–3 247 557 |
5 847 100 (5 185 984–6 566 636) |
6 652 840 (5 969 283–7 447 327) |
9 517 169 (8 599 529–10 544 702) |
25 253 888 (23 356 813–27 245 250) |
| Cases per 100 000 |
2643 (2374–2922) |
4333 (3844–4867) |
4878 (4377–5460) |
6837 (6178–7575) |
4574 (4231–4935) |
| YLD |
147 715 (103 706–203 433) |
258 411 (179 943–352 506) |
295 134 (205 286–407 958) |
346 117 (242 624–475054) |
1 070 358 (750 476–1 466 477) |
| Rate per 100 000 |
133 (93–183) |
192 (133–261) |
216 (151–299) |
249 (174–341) |
194 (136–266) |
| South Asia |
| Prevalence |
3 931 287 (3 566 450–4 315 347) |
7 908 429 (7 057 869–8 818 810) |
8 847 058 (7 976 611–9 814130) |
12 033 855 (10927 238–13 319010) |
33 081 529 (30 758 299–35 615 041) |
| Cases per 100 000 |
2786 (2528–3058) |
4415 (3940–4923) |
4975 (4485–5519) |
6763 (6141–7485) |
4664 (4336–5021) |
| YLD |
209 056 (146 539–286 880) |
359 966 (252 910–485 91 1) |
399 390 (275 291–552 742) |
457 025 (321 410–630 307) |
1 455 912 (1 023 230–1 979 015) |
| Rate per 100 000 |
148 (104–203) |
201 (141 –271) |
225 (155–311) |
257 (181 –354) |
205 (144–279) |
| Sub-Saharan Africa |
| Prevalence |
3 694 805 (3 352 273–4064 331) |
6 576 843 (5 912 292–7 295 890) |
6 363 670 (5 763 444–7 037 152) |
7182174 (6 591 941–7 868 098) |
24 215 356 (22 583 51 1–25 985 485) |
| Cases per 100 000 |
2866 (2600–3152) |
4460 (4009–4947) |
4877 (4417–5393) |
6493 (5959–7113) |
4387 (4092–4708) |
| YLD |
239 641 (167 087–325 126) |
355 441 (249 963–475 154) |
348 323 (244 318–470 735) |
331 536 (234 376–448 129) |
1 320 256 (937 865–1 765 546) |
| Rate per 100 000 |
186 (130–252) |
241 (170–322) |
267 (187–361) |
300 (212–405) |
239 (170–320) |
| North Africa and the Middle East |
| Prevalence |
751 019 (652 720–873 241) |
1 405 634 (1 230 855–1 586 991) |
1 443 894 (1 271 286–1 632 521) |
1 941 910 (1 732 125–2 175 269) |
5 591 434 (5 144 265–6 077 669) |
| Cases per 100 000 |
455 (1265–1692) |
2275 (1992–2569) |
2552 (2247–2885) |
3699 (3299–4143) |
2377 (2187–2584) |
| YLD |
30 533 (20 961–42 481) |
54000 (36 989–74 896) |
56 630 (38 685–79 072) |
63 515 (43 877–88 736) |
207 788 (144685–286 606) |
| Rate per 100 000 |
59 (41–82) |
87 (60–121) |
100 (68–140) |
121 (84–169) |
88 (62–122) |
| Global |
| Prevalence |
13 244 864 (11 950 478–14 667 046) |
25 468 776 (22 734486–28 377 208) |
27 358 599 (24 627 508–30 360 794) |
36 577 235(33 265 797–40 257 224) |
103 904 538 (96 545 635–11 1 630 666) |
| Cases per 100 000 |
2440 (2202–2703) |
3852 (3438–4292) |
4300 (3871–4772) |
5933 (5396–6530) |
4005 (3721–4302) |
| YLD |
711 795 (499 549–978 438) |
1 177 588 (826 177–1 586 023) |
1 264 660 (880 741–1 742 484) |
1 395 869 (982 697–1 908 896) |
4 662 724 (3 290 463–6 304 785) |
| Rate per 100 000 |
131 (92–180) |
178 (125–240) |
199 (138–274) |
226 (159–310) |
180 (127–243) |
